• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Medclair receives follow-on order of SEK 5.4 million

Medclair
Download the release

An established UK-based customer within the recycling segment has chosen to expand its existing solution for nitrous oxide handling and has placed a follow-on order valued at approximately SEK 5.4 million, with expected delivery in Q2 2026.

The collaboration between the parties continues to deepen as the need to manage nitrous oxide emissions within the recycling sector grows. Through this investment, the customer is able to scale its operations, while Medclair’s technology continues to play a central role in the transition towards more sustainable processes.
As in the healthcare sector, we are seeing that customers in other segments often return with additional orders.

– It is encouraging to see how our partnership with the customer has developed over a short period of time. Since the initial order in 2025 of SEK 4.4 million, we have delivered several smaller add-ons, and with this follow-on order of SEK 5.4 million, the customer is more than doubling its capacity. This is a pattern we recognize well from the healthcare sector: once our solutions are in place and delivering value, the business tends to grow organically. For us, this confirms that our key priority is to continue winning new customers, as we know that each new installation carries significant long-term growth potential, says CEO Jonas Lundh.

Jonas Lundh
CEO
Medclair AB

Contacts
For further information, please contact:
Jonas Lundh, Medclair AB (publ), Phone: +46 76 193 90 90, Email: jonas.lundh@medclair.com

About Us
Medclair is a Swedish cleantech company and a leader in safe and sustainable nitrous oxide management. With operations in twenty countries, Medclair provides innovative solutions that significantly reduce the climate impact of nitrous oxide while improving workplace safety.

The company is listed on NGM Nordic SME. For more information, please visit www.medclair.com.

This information is information that Medclair is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-23 11:35 CET.

Attachments
Medclair receives follow-on order of SEK 5.4 million